X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (245) 245
humans (167) 167
animals (118) 118
staurosporine - pharmacology (112) 112
apoptosis (91) 91
staurosporine - analogs & derivatives (85) 85
staurosporine (78) 78
apoptosis - drug effects (76) 76
male (67) 67
oncology (67) 67
female (65) 65
enzyme inhibitors - pharmacology (51) 51
cells, cultured (50) 50
rats (46) 46
mice (45) 45
adult (44) 44
pharmacology & pharmacy (42) 42
staurosporine - adverse effects (42) 42
cancer (40) 40
middle aged (40) 40
dose-response relationship, drug (39) 39
protein-kinase-c (39) 39
staurosporine - therapeutic use (36) 36
aged (33) 33
cell biology (33) 33
protein kinase c - antagonists & inhibitors (33) 33
cell line, tumor (31) 31
expression (30) 30
hematology (30) 30
staurosporine - administration & dosage (30) 30
biochemistry & molecular biology (29) 29
cell survival - drug effects (29) 29
activation (28) 28
cells (28) 28
neurosciences (28) 28
in-vitro (27) 27
phosphorylation (27) 27
chemotherapy (25) 25
leukemia, myeloid, acute - drug therapy (25) 25
mutation (25) 25
research (25) 25
antineoplastic agents - pharmacology (23) 23
signal transduction (23) 23
time factors (23) 23
antineoplastic agents - therapeutic use (22) 22
death (22) 22
kinases (22) 22
protein kinase inhibitors - pharmacology (22) 22
proteins (22) 22
toxicology (22) 22
analysis (21) 21
apoptosis - physiology (21) 21
cell line (21) 21
article (20) 20
fms-like tyrosine kinase 3 - genetics (20) 20
leukemia (20) 20
neurons - drug effects (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
inhibition (19) 19
staurosporine - pharmacokinetics (19) 19
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
medicine & public health (18) 18
protein kinases (18) 18
cell-death (17) 17
cytotoxicity (17) 17
flow cytometry (17) 17
leukemia, myeloid, acute - genetics (17) 17
oxidative stress (17) 17
protein kinase c - metabolism (17) 17
research article (17) 17
treatment outcome (17) 17
ucn-01 (17) 17
caspases - metabolism (16) 16
health aspects (16) 16
medicine (16) 16
midostaurin (16) 16
protein kinase inhibitors - therapeutic use (16) 16
rats, sprague-dawley (16) 16
staurosporine - toxicity (16) 16
toxicity (16) 16
abridged index medicus (15) 15
caspase 3 - metabolism (15) 15
inhibitors (15) 15
multidisciplinary sciences (15) 15
neoplasms - drug therapy (15) 15
neurons (15) 15
selective inhibitor (15) 15
antineoplastic agents - adverse effects (14) 14
blotting, western (14) 14
caspase-3 (14) 14
flt3 (14) 14
medical research (14) 14
phase-i (14) 14
protein kinase c (14) 14
acute myeloid leukemia (13) 13
caspase 3 (13) 13
cell death (13) 13
fms-like tyrosine kinase 3 - antagonists & inhibitors (13) 13
mutations (13) 13
neurons - cytology (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2530 - 2541
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 04/2012, Volume 97, Issue 4, pp. E528 - E536
Context and Objective: We have studied the antitumor activity of a novel cyclic amide, CLM94, with anti-vascular endothelial growth factor (VEGF) receptor-2... 
GROWTH-FACTOR RECEPTOR | CELLS | APOPTOSIS | FINE-NEEDLE-ASPIRATION | STAUROSPORINE | ENDOCRINOLOGY & METABOLISM | COMBINATION | CARCINOMA | THIAZOLIDINEDIONES | EXPRESSION | PROTEIN-KINASE INHIBITORS | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Thyroid Neoplasms - blood supply | Humans | Thyroid Carcinoma, Anaplastic | Drugs, Investigational - therapeutic use | Microvessels - pathology | Male | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - metabolism | Neoplasm Proteins - metabolism | Drugs, Investigational - chemistry | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Receptor, Epidermal Growth Factor - metabolism | Saccharin - chemistry | Benzamides - therapeutic use | Protein Processing, Post-Translational - drug effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Phosphorylation - drug effects | Tumor Cells, Cultured | Angiogenesis Inhibitors - adverse effects | Benzamides - adverse effects | Saccharin - adverse effects | Saccharin - therapeutic use | Benzamides - chemistry | Saccharin - analogs & derivatives | Angiogenesis Inhibitors - pharmacology | Microvessels - drug effects | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Antineoplastic Agents - chemistry | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | Thyroid Neoplasms - drug therapy | Tumor Burden - drug effects | Mice, Nude | Cell Line, Tumor | Mice | Saccharin - pharmacology | Angiogenesis Inhibitors - chemistry | Thyroid Neoplasms - metabolism | Thyroid Neoplasms - pathology | Cell proliferation | Phosphorylation | amides | Epidermal growth factor receptors | thyroid cancer | Gene expression | Endothelial cells | Antitumor activity | Microvasculature | Skin | Vascular endothelial growth factor | Cell migration | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 276 - 281
Journal Article
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2013, Volume 31, Issue 5, pp. 1217 - 1227
Background The PI3K-Akt pathway is frequently activated in acute leukemias and represents an important therapeutic target. UCN-01 and perifosine are known to... 
Medicine & Public Health | Perifosine | Akt inhibition | Acute leukemia | Oncology | Pharmacology/Toxicology | UCN-01 | MAMMALIAN TARGET | SIGNAL-TRANSDUCTION PATHWAYS | ADVANCED SOLID TUMORS | CLINICAL-TRIAL | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOID-LEUKEMIA | INTERNATIONAL WORKING GROUP | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | AKT INHIBITOR PERIFOSINE | HEMATOLOGIC MALIGNANCIES | Leukocytes, Mononuclear - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Staurosporine - analogs & derivatives | Leukemia - metabolism | Antineoplastic Agents - administration & dosage | Phosphorylcholine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Phosphorylcholine - administration & dosage | Staurosporine - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Phosphorylcholine - pharmacokinetics | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Proto-Oncogene Proteins c-akt - metabolism | Myelodysplastic Syndromes - drug therapy | Protein Kinase Inhibitors - pharmacokinetics | Myelodysplastic Syndromes - metabolism | Staurosporine - adverse effects | Leukemia - drug therapy | Treatment Outcome | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Phosphorylcholine - adverse effects | Aged | Staurosporine - administration & dosage | Complications and side effects | Enzyme inhibitors | Leukemia | Dosage and administration | Genetic aspects | Research | Drug therapy | Myelodysplastic syndromes | Studies | Cancer therapies | Analysis | Pharmaceutical sciences | Index Medicus | akt inhibition | perifosine
Journal Article
Life Sciences, ISSN 0024-3205, 2008, Volume 82, Issue 1, pp. 68 - 78
Stroke is a life-threatening disease characterized by rapidly developing clinical signs of focal or global disturbance of cerebral function due to cerebral... 
Oxidative stress | Stroke | Glabridin | Neurons | Apoptosis | MEDICINE, RESEARCH & EXPERIMENTAL | INDUCED NEURONAL APOPTOSIS | STAUROSPORINE-INDUCED APOPTOSIS | CULTURED NEURONS | apoptosis | stroke | neurons | CELL-DEATH | P-GLYCOPROTEIN | RAT HIPPOCAMPAL-NEURONS | ANTIOXIDANT CONSTITUENTS | CEREBRAL-ARTERY OCCLUSION | PHARMACOLOGY & PHARMACY | glabridin | SUPEROXIDE-DISMUTASE | oxidative stress | Neuroprotective Agents - therapeutic use | Neurons - pathology | Phenols - isolation & purification | Apoptosis - drug effects | Glutathione - metabolism | Male | Brain - metabolism | Brain - blood supply | Infarction, Middle Cerebral Artery - complications | Neuroprotective Agents - adverse effects | Neurons - drug effects | Superoxide Dismutase - metabolism | Disease Models, Animal | In Situ Nick-End Labeling | Malondialdehyde - metabolism | Cell Survival - drug effects | Stroke - prevention & control | Isoflavones - isolation & purification | Glycyrrhiza - chemistry | Rats | Rats, Sprague-Dawley | Blotting, Western | Brain - drug effects | Stroke - etiology | Animals | Phenols - adverse effects | Neuroprotective Agents - isolation & purification | Phenols - therapeutic use | Isoflavones - adverse effects | Brain - pathology | Isoflavones - therapeutic use | In Vitro Techniques | Brain | Neuroprotection | Animal models | Cell survival | Staurosporine | Cortex | Cytotoxicity | Superoxide dismutase | Caspase-3 | Neuromodulation | Proenzymes | Antioxidants | Flavonoids | Ischemia | Cerebral blood flow | Injuries | Glutathione | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article